Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qianfoshan Hospital
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
\- 1. Patients with histologically confirmed prostate cancer (PC) deemed suitable for endocrine therapy (excluding neoadjuvant endocrine therapy).
2\. At least 18 years old 3. Prescribed 3.6 mg goserelin every 4 weeks as monotherapy or in combination with anti-androgen therapy.
You may not be if
1\. Hypersensitivity to LHRH, its analogs, or any component of goserelin. 2. Previous or concurrent hormone therapy, except for conventional anti-androgen therapy administered within 2 weeks before goserelin treatment.
3\. Diagnosis or suspicion of hormone-resistant PC, history of hypophysectomy, adrenalectomy, or pituitary lesions.
4.Scheduled for radical radiotherapy (adjuvant radiotherapy post-radical prostatectomy \[RP\] combined with goserelin is permitted) or planned neoadjuvant hormone therapy prior to RP.
Clareo Health | Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study
